HomeCompareCASBF vs ADC

CASBF vs ADC: Dividend Comparison 2026

CASBF yields 51.81% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $149.0K in total portfolio value· pulled ahead in Year 6
10 years
CASBF
CASBF
● Live price
51.81%
Share price
$3.86
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$7.71
Full CASBF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — CASBF vs ADC

📍 ADC pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCASBFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CASBF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CASBF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF
Annual income on $10K today (after 15% tax)
$4,404.15/yr
After 10yr DRIP, annual income (after tax)
$6.55/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,671.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + ADC for your $10,000?

CASBF: 50%ADC: 50%
100% ADC50/50100% CASBF
Portfolio after 10yr
$104.5K
Annual income
$40,402.50/yr
Blended yield
38.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CASBF
No analyst data
Altman Z
2.6
Piotroski
4/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys
0
ADC buys
0
No recent congressional trades found for CASBF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCASBFADC
Forward yield51.81%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.4%
Portfolio after 10y$30.0K$178.9K
Annual income after 10y$7.71$80,797.29
Total dividends collected$6.0K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CASBF vs ADC ($10,000, DRIP)

YearCASBF PortfolioCASBF Income/yrADC PortfolioADC Income/yrGap
1$13,291$2,590.67$10,990$580.36+$2.3KCASBF
2$15,830$1,608.96$12,301$860.26+$3.5KCASBF
3$17,834$895.50$14,104$1,298.62+$3.7KCASBF
4$19,553$471.42$16,691$2,008.16+$2.9KCASBF
5$21,164$241.53$20,580$3,205.09+$584.00CASBF
6← crossover$22,767$122.16$26,754$5,330.02$4.0KADC
7$24,422$61.41$37,196$9,345.14$12.8KADC
8$26,163$30.78$56,244$17,523.09$30.1KADC
9$28,010$15.41$94,286$35,736.21$66.3KADC
10$29,978$7.71$178,949$80,797.29$149.0KADC

CASBF vs ADC: Complete Analysis 2026

CASBFStock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CASBF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHDCASBF vs JEPICASBF vs OCASBF vs KOCASBF vs MAINCASBF vs NNNCASBF vs EPRTCASBF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.